BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27695964)

  • 21. Cytomegalovirus reactivation after matched sibling donor reduced-intensity conditioning allogeneic hematopoietic stem cell transplant correlates with donor killer immunoglobulin-like receptor genotype.
    Sobecks RM; Askar M; Thomas D; Rybicki L; Kalaycio M; Dean R; Avery R; Mossad S; Copelan E; Bolwell BJ
    Exp Clin Transplant; 2011 Feb; 9(1):7-13. PubMed ID: 21605017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of KIR genes in HLA-identical sibling hematopoietic stem cell transplantation in Thai patients with leukemia.
    Wongwuttisaroj N; Vejbaesya S; Chongkolwatana V; Issaragrisil S
    J Med Assoc Thai; 2012 Oct; 95(10):1261-5. PubMed ID: 23193738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Study on the behavior of NK cell KIRs of donor/recipient pairs in HLA matched unrelated allo-HSCT].
    Bao XJ; He J; Chen ZX; Wu DP; Yao L; Yuan XN; Cen JN; Qiu QC; Di WY; Zhang H; Zhang J; Zhou XH; Xu HX
    Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):510-3. PubMed ID: 18078124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compound KIR-HLA genotype analyses in the Iranian population by a novel PCR-SSP assay.
    Tajik N; Shahsavar F; Nasiri M; Radjabzadeh MF
    Int J Immunogenet; 2010 Jun; 37(3):159-68. PubMed ID: 20193031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The investigation of killer-cell immunoglobulin-like receptors (KIRs) and their HLA ligands in Iranian patients with myasthenia gravis.
    Jalalvand M; Beigmohammadi F; Soltani S; Ehsan S; Rajabkhah S; Madreseh E; Akhtari M; Jamshidi A; Farhadi E; Mahmoudi M; Nafissi S
    Clin Neurol Neurosurg; 2024 Mar; 238():108171. PubMed ID: 38422742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of "Killer Immunoglobulin-Like Receptor /Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival.
    Beksac K; Beksac M; Dalva K; Karaagaoglu E; Tirnaksiz MB
    PLoS One; 2015; 10(7):e0132526. PubMed ID: 26181663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort.
    Ishida Y; Nakashima C; Kojima H; Tanaka H; Fujimura T; Matsushita S; Yamamoto Y; Yoshino K; Fujisawa Y; Otsuka A; Kabashima K
    Sci Rep; 2018 Oct; 8(1):15962. PubMed ID: 30374122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.
    Bernson E; Hallner A; Sander FE; Nicklasson M; Nilsson MS; Christenson K; Aydin E; Liljeqvist JÅ; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
    Cancer Immunol Res; 2018 Sep; 6(9):1110-1119. PubMed ID: 29980537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequencies of killer immunoglobulin-like receptor genotypes influence susceptibility to spontaneous abortion.
    Nowak I; Malinowski A; Tchorzewski H; Barcz E; Wilczynski JR; Grybos M; Kurpisz M; Luszczek W; Banasik M; Reszczynska-Slezak D; Majorczyk E; Wisniewski A; Senitzer D; Yao Sun J; Kusnierczyk P
    J Appl Genet; 2009; 50(4):391-8. PubMed ID: 19875891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Distribution of immunoglobulin like receptor gene in Han population in China and the impact thereof on the HLA-identical sibling hematopoietic stem cell transplantation].
    Dou LP; DA WM; Zhao DD; Wang C; Lu XC; Kang HY; Yan P; Wang FF; Zhu HY; Li HH; Gao CJ; Yu L
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3111-4. PubMed ID: 18269867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
    Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
    Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
    Shimoni A; Vago L; Bernardi M; Yerushalmi R; Peccatori J; Greco R; Shem-Tov N; Lo Russo A; Danylesko I; Apel A; Bonini C; Lupo Stanghellini MT; Nagler A; Ciceri F
    Am J Hematol; 2017 Oct; 92(10):1011-1019. PubMed ID: 28631269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KIR2DS3 is associated with protection against acute myeloid leukemia.
    Shahsavar F; Tajik N; Entezami KZ; Fallah Radjabzadeh M; Asadifar B; Alimoghaddam K; Ostadali Dahaghi M; Jalali A; Ghashghaie A; Ghavamzadeh A
    Iran J Immunol; 2010 Mar; 7(1):8-17. PubMed ID: 20371915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.
    Heidenreich F; Falk B; Baldauf H; Massalski C; Schäfer G; Rücker-Braun E; Altmann H; Sauter J; Solloch UV; Lange V; Stölzel F; Röllig C; Middeke JM; von Bonin M; Thiede C; Schäfer-Eckart K; Müller-Tidow C; Krause SW; Kraus S; Kaufmann M; Hänel M; Serve H; Neubauer A; Bornhäuser M; Schmidt AH; Schetelig J
    Blood Adv; 2023 Jul; 7(13):2994-3004. PubMed ID: 36689727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of killer cell immunoglobulin-like receptor (KIR) genes and their HLA ligands with susceptibility to Behçet's‎ disease.
    Mohammad-Ebrahim H; Kamali-Sarvestani E; Mahmoudi M; Beigy M; Karami J; Ahmadzadeh N; Shahram F
    Scand J Rheumatol; 2018 Mar; 47(2):155-163. PubMed ID: 28862099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage.
    Canossi A; Aureli A; Del Beato T; Rossi P; Franceschilli L; De Sanctis F; Sileri P; di Lorenzo N; Buonomo O; Lauro D; Venditti A; Sconocchia G
    J Transl Med; 2016 Aug; 14(1):239. PubMed ID: 27519478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The beneficial impact of missing KIR ligands and absence of donor KIR2DS3 gene on outcome following unrelated hematopoietic SCT for myeloid leukemia in the Chinese population.
    Wu GQ; Zhao YM; Lai XY; Luo Y; Tan YM; Shi JM; Li L; Zheng WY; Zhang J; Hu XR; Jin AY; He JS; Xie WZ; Ye XJ; Cai Z; Lin MF; Huang H
    Bone Marrow Transplant; 2010 Oct; 45(10):1514-21. PubMed ID: 20173784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Killer Immunoglobulin-Like Receptor-Ligand Interactions Predict Clinical Outcomes following Unrelated Donor Transplantations.
    Krieger E; Sabo R; Moezzi S; Cain C; Roberts C; Kimball P; Chesney A; McCarty J; Keating A; Romee R; Wiedl C; Qayyum R; Toor A
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):672-682. PubMed ID: 31676338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells.
    Vineretsky KA; Karagas MR; Christensen BC; Kuriger-Laber JK; Perry AE; Storm CA; Nelson HH
    Cancer Res; 2016 Jan; 76(2):370-6. PubMed ID: 26744525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
    Terszowski G; Klein C; Stern M
    J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.